Biotech financing has returned from its giddy heights at the beginning of the year. Funding declined by 27% from the first quarter's $17 billion to reach >$12 billion, and partnerships deals were hit hardest, declining by almost three-quarters. Even with a biotech market garnering double-digit gains in the second quarter, the amount raised by follow-on financings was off by almost two-thirds. Venture capital and public funding have remained relatively stable; both managed to eke out moderate increases.
Rights and permissions
About this article
Cite this article
Lawrence, S. Biotech financing retrenches in Q2. Nat Biotechnol 24, 883 (2006). https://doi.org/10.1038/nbt0806-883
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0806-883
This article is cited by
-
Erratum: Biotech financing retrenches in Q2
Nature Biotechnology (2006)